Healthcare - Biotechnology - NASDAQ - US
$ 17.85
-6.25 %
$ 668 M
Market Cap
12.4
P/E
BALANCE SHEET
469 M
ASSETS
227 M
LIABILITIES
242 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Entrada Therapeutics, Inc.
| Current Assets | 370 M |
| Cash & Short-Term Investments | 352 M |
| Receivables | 0 |
| Other Current Assets | 17.8 M |
| Non-Current Assets | 99.4 M |
| Long-Term Investments | 0 |
| PP&E | 92.7 M |
| Other Non-Current Assets | 6.74 M |
| Current Liabilities | 159 M |
| Accounts Payable | 3.28 M |
| Short-Term Debt | 15.8 M |
| Other Current Liabilities | 140 M |
| Non-Current Liabilities | 68 M |
| Long-Term Debt | 60.3 M |
| Other Non-Current Liabilities | 7.72 M |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| ASSETS | |||||
| Cash & Cash Equivalents | 67.6 | 45.2 | 291.1 | 39.0 | 16.8 |
| Short Term Investments | 284.4 | 143.6 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 27.7 | 21.2 | 7.6 | 0.9 | 0.6 |
| Total Current Assets | 369.8 | 209.9 | 298.7 | 39.9 | 17.4 |
| PP&E | 92.7 | 33.0 | 6.3 | 3.0 | 0.8 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 0 | 4.0 | 0 | 0 | 0 |
| Other Long Term Assets | 6.7 | 5.2 | 0.9 | 0.5 | (0.8) |
| Other Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 469.2 | 252.1 | 305.8 | 43.5 | 18.2 |
| LIABILITIES | |||||
| Accounts Payable | 3.3 | 6.0 | 0.7 | 1.6 | 0.7 |
| Short Term Debt | 15.8 | 16.8 | 0 | 0 | 0 |
| Other Current Liabilities | 3.4 | (0.8) | 6.0 | 1.8 | 1.2 |
| Total Current Liabilities | 158.8 | 22.0 | 6.7 | 3.4 | 1.9 |
| Long Term Debt | 60.3 | 17.5 | 0 | 0 | 0 |
| Deferred Tax Income | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0.4 | 0 | 31.8 |
| Total Liabilities | 226.8 | 39.5 | 7.1 | 85.0 | 33.8 |
| EQUITY | |||||
| Common Stock | 3 K | 3 K | 3 K | 1 K | 1 K |
| Retained Earnings | (195.0) | (188.3) | (93.7) | (42.5) | (16.0) |
| Other Accumulative Comprehensive Income/Loss | 0.2 | (2.1) | (305.8) | (81.7) | (31.8) |
| Total Equity | 242.4 | 212.6 | 298.7 | (41.5) | (15.5) |
| Total Liabilities and Equity | 469.2 | 252.1 | 305.8 | 43.5 | 18.2 |
| SHARES OUTSTANDING | |||||
| Common Shares Outstanding | 33.1 | 31.3 | 31.2 | 31.2 | 31.2 |